Rankings
▼
Calendar
EBS Q2 2018 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena
EBS
Emergent BioSolutions Inc.
$433M
Q2 2018 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$220M
+118.5% YoY
Gross Profit
$110M
50.0% margin
Operating Income
$67M
30.3% margin
Net Income
$50M
22.8% margin
EPS (Diluted)
$0.98
QoQ Revenue Growth
+86.9%
Cash Flow
Operating Cash Flow
$35M
Free Cash Flow
$21M
Stock-Based Comp.
$4M
Balance Sheet
Total Assets
$1.1B
Total Liabilities
$201M
Stockholders' Equity
$938M
Cash & Equivalents
$190M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$220M
$101M
+118.5%
Gross Profit
$110M
$41M
+171.4%
Operating Income
$67M
$9M
+683.2%
Net Income
$50M
$5M
+985.4%
← FY 2018
All Quarters
Q3 2018 →